Turnstone Biologics Corp.
TSBXDelisted Aug 11, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764974
Turnstone Biologics Corp. was delisted on Aug 11, 2025; its insiders filed their last Form 4 on Aug 12, 2025; 23 institutions reported holding it in 13F filings for Q2 2025, worth $3.03M in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in Turnstone Biologics Corp. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
TSBX is no longer listed, so this page shows Q2 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 23
- 0 vs. Q1 2025
- Shares held
- 8.43M
- −1.96M (−18.8%) vs. Q1 2025
- Total value
- $3.03M
- −$1.23M (−28.9%) vs. Q1 2025
- New holders
- 3
- 4 more added
- Sold out
- 3
- 8 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TSBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 23 | $3.03M |
| Q1 2025 | 23 | $4.26M |
| Q4 2024 | 28 | $5.51M |
| Q3 2024 | 24 | $6.37M |
| Q2 2024 | 47 | $33.3M |
| Q1 2024 | 40 | $35.0M |
| Q4 2023 | 36 | $33.1M |
| Q3 2023 | 35 | $48.0M |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Turnstone Biologics Corp.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 71 | $25 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 121 | $43 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 150 | $54 | 0.00% | −891,381−100.0% | Reduced |
| JPMorgan Chase & Co | 158 | $57 | 0.00% | −38−19.4% | Reduced |
| BlackRock, Inc. | 1,066 | $383 | 0.00% | −41,334−97.5% | Reduced |
| Tower Research Capital LLC (TRC) | 4,741 | $1.70K | 0.00% | −20−0.4% | Reduced |
| Acadian Asset Management LLC | 16,430 | $4.00K | 0.00% | −1,403−7.9% | Reduced |
| Northern Trust Corp | 18,405 | $6.61K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 37,786 | $13.6K | 0.00% | +2,045+5.7% | Added |
| GTS Securities LLC | 45,163 | $16.2K | 0.00% | +45,163 | New |
| Renaissance Technologies LLC | 47,100 | $16.9K | 0.00% | +6,900+17.2% | Added |
| HRT Financial LP | 55,859 | $20.0K | 0.00% | +43,776+362.3% | Added |
| Susquehanna International Group, LLP | 79,305 | $28.5K | 0.00% | +54,000+213.4% | Added |
| Vanguard Group Inc | 83,926 | $30.1K | 0.00% | −431,161−83.7% | Reduced |
| Deltec Asset Management LLC | 106,057 | $38.1K | 0.01% | +106,057 | New |
| Geode Capital Management, LLC | 130,077 | $46.7K | 0.00% | −6,703−4.9% | Reduced |
| Citadel Advisors LLC | 208,887 | $75.0K | 0.00% | +208,887 | New |
| 72 Investment Holdings, LLC | 549,980 | $197.4K | 0.52% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 816,923 | $293.3K | 0.00% | −62,010−7.1% | Reduced |
| Takeda Pharmaceutical Co Ltd | 895,824 | $321.6K | 1.64% | 00.0% | Unchanged |
| BML Capital Management, LLC | 1,103,386 | $396.1K | 0.30% | 00.0% | Unchanged |
| FMR LLC | 1,133,987 | $407.1K | 0.00% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 3,099,265 | $1.11M | 0.03% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 0 | $0 | 0.00% | −932,348−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −38,858−100.0% | Sold out |
| Nordwand Advisors, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |